VBIV - VBI Vaccines

-

$undefined

N/A

(N/A)

VBI Vaccines NASDAQ:VBIV VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Location: | Website: www.vbivaccines.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

1.04%

Insider Ownership

6.77%

Institutional Own.

13.04%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PreHevbrio (Sci-B-Vac®) Details
Hepatitis B, Hepatitis B vaccine, Pain

Approved

Quarterly sales

VBI-1901 (eVLP) Details
Glioblastoma, Cancer

Phase 2b

Data readout

VBI-2601 (BRII-179) combo w/ PEG-IFNα Details
Chronic hepatitis B, Hepatitis B

Phase 2

Update

VBI-1901 (eVLP) Details
Glioblastoma, Cancer

Phase 2

Initiation

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1

Data readout

VBI-1501 Details
Cytomegalovirus

Phase 1

Update